Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Change in Directorate

 1. Resignation of Mr. S N Kamath from the position of Managing Director as well as membership from all committees of board of the Company with immediate effect i.e. May 11, 2021; 2. Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company for a further period of 5 years with effect from 26th May, 2021 to 25th May, 2026; 3. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company for a period of Three years with effect from 11th May, 2021 to 10th May, 2024.
11-05-2021
Bigul

BLISS GVS PHARMA LTD. - 506197 - Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2021

 1. Audited standalone and consolidated financial results of the Company for the quarter and year ended March 31, 2021 along with the audit report with declaration of unmodified opinion 2. Recommended Final dividend of 50% i.e. 0.50 paisa per equity share on face value of Rs. 1/- each for the financial year ended March 31, 2021 3.Re-appointment of M/s. BDO India LLP, Chartered Accountant having LLP registration no. AAB-7880 as Internal Auditor 4. Issue & Allotment of 2,10,500 Equity Shares of face value of Rs. 1 each of the Company under 'Bliss GVS Pharma Limited-Employee Stock Option Plan 2019' 5.Re-appointment of Mr. Santosh Laxman Parab (DIN:01622988), as an Non-Executive Independent Director of the Company 6. Resignation of Mr. S N Kamath from the position of Managing Director 7. Appointment of Mr. Gagan Harsh Sharma (DIN:07939421) as Managing Director of the Company 8. Reconstitution of Committees
11-05-2021
Bigul

BLISS GVS PHARMA LTD. - 506197 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper advertisement pertaining to notice of Meeting of the Board of Directors of the Company scheduled to be held on Tuesday, May 11, 2021, at the registered office of the Company inter alia to consider and approve Audited Standalone and Consolidated Financial Statements and Results for the quarter and year ended March 31, 2021 published in 'The Economic Times & The Free Press Journal' an English Daily and 'Maharashtra Times & Navshakti' a Regional Daily, on May 05, 2021.
05-05-2021
Bigul

Bliss GVS Pharma Ltd - 506197 - Board Meeting Intimation for Board Meeting Intimation To Consider Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2021 And Recommendation Of Dividend, If Any

 BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/05/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board Meeting of the Company will be held on Tuesday, May 11, 2021 at the registered office of the Company, inter alia, to transact the following: a) To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2021 along with the Statement of Assets and Liabilities, Cash Flow Statement and take note of Audit Report with modified opinion, if any, thereon.; b) To consider and approve the Audited Standalone and Consolidated Financial Statement of the Company for the financial year ended March 31, 2021; and c) To discuss and recommend the Final Dividend, if any, for the financial year ended March 31, 2021.
03-05-2021
Bigul

Bliss GVS Pharma Ltd - 506197 - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2021

 Please find enclosed herewith the half yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2021
29-04-2021
Bigul

Bliss GVS Pharma Ltd - 506197 - Certificate Under Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended March 31, 2021

 Please find enclosed herewith certificate under Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2021
29-04-2021
Bigul

Bliss GVS Pharma Ltd - 506197 - Shareholding for the Period Ended March 31, 2021

 Bliss GVS Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here
20-04-2021
Bigul

Bliss GVS Pharma Ltd - 506197 - Statement Of Investor Complaints For The Quarter Ended March 2021

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Aditi BhattDesignation :- Company Secretary and Compliance Officer
20-04-2021
Bigul

BLISS GVS PHARMA LTD. - 506197 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2021. Kindly take the same on record.
14-04-2021
Bigul

BLISS GVS PHARMA LTD. - 506197 - Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''Listing Regulations'') read with Para B of Part A of Schedule III of Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, we would like to inform you that, the Members of Nomination and Remuneration Committee of the Board of Directors of the Company yesterday i.e. April 05, 2021 through circular resolution have approved grant of 7,30,000 Options out of balance 32,39,000 Options under Bliss GVS Pharma Limited- Employee Stock Options Plan 2019 ('ESOP-2019') to the eligible employees as per the details mentioned in 'Annexure -A'. Total number of shares covered by ESOP-2019 is 60,00,000 Equity Shares. You are requested to take the aforementioned information on your records.
06-04-2021
Next Page
Close

Let's Open Free Demat Account